021003 Pang Slides

Information about 021003 Pang Slides

Published on April 16, 2008

Author: Alohomora

Source: authorstream.com

Content

Slide1:  The Challenge: Create a uniform approach for valuing specific compounds and R&D portfolios for market opportunity What is it worth? Using a Patient-based Approach to Market Valuation Benefits of Understanding Your Market:  Benefits of Understanding Your Market Market Assessment-understanding the dynamics and forces Technology and Product Evaluation-what are the opportunities Licensing negotiation-what is it worth under what scenario(s) Product selection-creating a strategic framework for R&D choicemaking Portfolio analysis-Given our strategic direction, what kind of pipeline do we want to construct? Marketing strategies Critical Business Decisions:  Critical Business Decisions Is there a licensing opportunity in this emerging therapy; and, what is the product’s potential market value when seeking a development/marketing partner? How should we focus our R&D portfolio? Some General Approaches:  Some General Approaches Comparables Incremental value Top-down Market Based models NPV Real options Bottom up or Patient Based Forecasting Some Key Questions:  Some Key Questions What is the size of the target market Patient population, i.e., epidemiology Segmentation What are the unmet needs in the target market? Clinical Gold Standard Market What are the regulatory hurdles? What is the competition within the target market? What is the reimbursement environment? Slide6:  Critical Information: The Market —Base Year Number of Treated Patients Compliance Rate Price = Sales Days of Therapy per Year X X X Reconciled with prescription volume and top-line sales. Slide7:  Critical Information: Patient Population *May apply to the incident or prevalent population, depending on the indication. Definitions Number of newly occurring cases in a given year Total number of persons with a particular disease Number of persons diagnosed by a physician with a particular disease in a given year* Incident population Prevalent population Diagnosed population Drug-treated population Number of diagnosed patients who are under the care of a physician and who have received a prescription drug regimen* Slide8:  Unmet Clinical Need Criteria Mortality Morbidity Pain Non-Pain Symptoms Disability Hospitalization Efficacy Compound Attributes Effect on Non-Pain Symptoms Overall Response Complete Response Effect on Mortality Effect on Pain Overall Response Effect on Potential for Complications Effect on Hospitalization Effect on Disability Disease Severity Unmet Product Need How serious is the disease? How effective is the gold-standard therapy? Complete Response Compound Attributes Side Effects Drug Interactions/ Contraindications Dosage Form Dosing Frequency Onset of Action Minor Significant Safety Convenience Patient-based Commercial Assessment :  Patient-based Commercial Assessment ASSUMPTION # 1 ASSUMPTION #2 ASSUMPTION #3 Patient-based Commercial Assessment :  Patient-based Commercial Assessment Diagnosis Rate Prevalence of Molecular Target Patient-based Commercial Assessment :  Patient-based Commercial Assessment Diagnosis Rate Prevalence of Molecular Target Clinical Unmet Need & Product Unmet Need Assessment of Product Compared to Current Gold Standard Primary research/Conjoint Analysis Competitive landscape Analog Models Sales and prescription audit data Market- and region-specific factors Patient-based Commercial Assessment :  Patient-based Commercial Assessment Diagnosis Rate Prevalence of Molecular Target Clinical Unmet Need & Product Unmet Need Assessment of Product Compared to Current Gold Standard Competitive landscape Primary research/Conjoint Analysis Analogue Models Sales and prescription audit data Market- and region-specific factors Degree of Clinical Advance (Improved efficacy, product attributes) Price/Demand Elasticity Regional Considerations Pricing Analysis will be further refined in Phase III/pre-launch Patient-based Commercial Assessment :  Patient-based Commercial Assessment Diagnosis Rate Prevalence of Molecular Target Clinical Unmet Need & Product Unmet Need Assessment of Product Compared to Current Gold Standard Competitive landscape Primary research/Conjoint Analysis Analogue Models Sales and prescription audit data Market- and region-specific factors Degree of Clinical Advance (Improved efficacy, product attributes) Price/Demand Elasticity Regional Considerations Pricing Analysis will be further refined in Phase III/pre-launch 5. Market Value = 2. Candidate Population x 3. Market Uptake x 4. Price Slide14:  Case Study-Licensing “CelGen Industries, Inc.” Medium-sized biotech firm Focus on cancer and inflammatory disease Potential in-licensing opportunity: “AntiMab’s” BT-504 “AntiMab” is a small biotech involved in the development of antibody therapeutics targeting cancer epitopes BT-504 is currently in Phase II development, to date has completed 2 Phase I trials 1 Phase II trial Product Overview: BT-504:  Target Oncology Indications: Non-Hodgkins lymphoma (NHL) Chronic Lymphocytic Leukemia (CLL) Acute Lymphocytic Leukemia (ALL) Clinical Data Favorable pharmacokinetics Phase I/II data shows good safety profile Preliminary activity in Phase I/II promising Internal R&D evaluation of BT-504 is positive Product Overview: BT-504 Tasks to Accomplish:  Tasks to Accomplish Your tasks are to: 1). Assess the market potential of BT-504 2.) Prioritize the value of three oncology indications (NHL, ALL, CLL) and advise on clinical development strategy. 3.) Provide a recommendation on in-licensing BT-504. (Based on current portfolio and assuming CelGen has the resources for a maximum of 4 products) CelGen’s Pipeline:  CelGen’s Pipeline Key Questions in the Market Assessment:  Key Questions in the Market Assessment 1. What is the size of the product’s target patient population? 2. How will the product be positioned within the market (first-line therapy, sub-segment of the population, etc.)—function of product profile compared with current gold standard therapy? 3. What peak-year uptake (%) can be expected? 4. What is a reasonable pricing scheme? 5. What is the value ($) of this market? Prevalence:  Prevalence Sales:  Sales Go to Spreadsheet:  Go to Spreadsheet Impact of Market Research on R&D:  Impact of Market Research on R&D Synergies with current R&D program Is the product aligned with CelGen’s internal capabilities/expertise? R&D Strategy Focus on oncology franchise? Risk/cost associated with developing internal R&D capabilities vs. Market Value of BT-504 Reallocation of resources to support in-licensed program Impact on R&D staff expertise, interest, and morale Strategic Determinations:  Strategic Determinations 1. What is the market value of BT-504? 2. Should BT-504 be in-licensed? 3. Which indication(s) should be prioritized? 4. What is the impact of in-licensing BT-504 on CelGen’s R&D portfolio? Case Outcome:  Case Outcome Product In-licensing agreement $9 million (1995 US$) upfront payments in equity and investment fees $17.5 million equity funding prior to approval $30.5 million in milestone and option payments Total potential value of the collaboration $57 million. Co-promotion in the U.S., CelGen has complete commercialization rights ex-US. Developed for NHL Approval for second-line Rx of CD20+ NHL in US 1997, Europe 1998, extensive off-label use 1st line. Clinical studies ongoing for first-line NHL, CLL, aggressive NHL. G7 market value 2000 $400M+ The Value of a Patient-Based Approach to Market Strategy:  The Value of a Patient-Based Approach to Market Strategy Understanding your markets can help craft strategy Licensing opportunities R&D activity prioritization and portfolio construction Foundation for NPV and other valuation approaches Better long-term strategic decision-making

Related presentations


Other presentations created by Alohomora

Learning The Months Of the Year
02. 11. 2007
0 views

Learning The Months Of the Year

HIV STDs Presentation
06. 08. 2007
0 views

HIV STDs Presentation

17 Supply Chain
15. 11. 2007
0 views

17 Supply Chain

duxbury asa
04. 10. 2007
0 views

duxbury asa

Review Week 19
04. 10. 2007
0 views

Review Week 19

ChaneyPres2
16. 10. 2007
0 views

ChaneyPres2

collab filtering tutorial
17. 10. 2007
0 views

collab filtering tutorial

Winderemere Shibboleth 2005 11
17. 10. 2007
0 views

Winderemere Shibboleth 2005 11

1940 1950
23. 10. 2007
0 views

1940 1950

Curso Chagas clase 1
23. 10. 2007
0 views

Curso Chagas clase 1

eplan en
26. 11. 2007
0 views

eplan en

Angiosperms and Gymnosperms
07. 12. 2007
0 views

Angiosperms and Gymnosperms

ns1
13. 10. 2007
0 views

ns1

dahl poster
26. 08. 2007
0 views

dahl poster

RuneGangeskar
07. 11. 2007
0 views

RuneGangeskar

VOCsLouisville 5 18a AHewitt
07. 11. 2007
0 views

VOCsLouisville 5 18a AHewitt

darkts mlecture
13. 11. 2007
0 views

darkts mlecture

Ipertesto
24. 10. 2007
0 views

Ipertesto

SheepGoatHealth
15. 11. 2007
0 views

SheepGoatHealth

IntroLFG2
22. 11. 2007
0 views

IntroLFG2

HERC Waste Summit
14. 11. 2007
0 views

HERC Waste Summit

ENGS11 2007 ERP
28. 12. 2007
0 views

ENGS11 2007 ERP

Kerr
28. 11. 2007
0 views

Kerr

Bourgault
03. 01. 2008
0 views

Bourgault

CHM 103 Lecture 17 S07
03. 01. 2008
0 views

CHM 103 Lecture 17 S07

Stock
26. 10. 2007
0 views

Stock

russian project proposals plus
05. 01. 2008
0 views

russian project proposals plus

Heredity
06. 08. 2007
0 views

Heredity

interest
06. 08. 2007
0 views

interest

HowAdultsReallyLearn PPt1 13 05
06. 08. 2007
0 views

HowAdultsReallyLearn PPt1 13 05

neutrino
05. 01. 2008
0 views

neutrino

Early chemotherapy
15. 10. 2007
0 views

Early chemotherapy

pdb95
15. 10. 2007
0 views

pdb95

18 DanceLanguage
16. 10. 2007
0 views

18 DanceLanguage

Hermez
06. 08. 2007
0 views

Hermez

NIC
15. 10. 2007
0 views

NIC

indicators
23. 10. 2007
0 views

indicators

BodyPsychotherapy
17. 10. 2007
0 views

BodyPsychotherapy

cikm05 ium
19. 11. 2007
0 views

cikm05 ium

Strock
28. 02. 2008
0 views

Strock

Okereke King County
26. 08. 2007
0 views

Okereke King County

wap cfprog
25. 03. 2008
0 views

wap cfprog

Quotable quotes 070508
26. 03. 2008
0 views

Quotable quotes 070508

e31 glob
07. 04. 2008
0 views

e31 glob

WCG CHAPTER13
27. 03. 2008
0 views

WCG CHAPTER13

KeenWhatsBehindRecor dDebt
09. 04. 2008
0 views

KeenWhatsBehindRecor dDebt

lecture05
10. 04. 2008
0 views

lecture05

GEO205 powerpoint 10
13. 04. 2008
0 views

GEO205 powerpoint 10

4903
14. 04. 2008
0 views

4903

wward
17. 10. 2007
0 views

wward

UMBC presentation 050406
17. 04. 2008
0 views

UMBC presentation 050406

Eureka Gold Real Estate
22. 04. 2008
0 views

Eureka Gold Real Estate

IntroPolicy
07. 10. 2007
0 views

IntroPolicy

ncb klein brief01feb06
04. 03. 2008
0 views

ncb klein brief01feb06

26 canadian
18. 06. 2007
0 views

26 canadian

20 Grund Kurs Kurortmedizin 2005
18. 06. 2007
0 views

20 Grund Kurs Kurortmedizin 2005

wrapebs
18. 06. 2007
0 views

wrapebs

wirsindspoe
18. 06. 2007
0 views

wirsindspoe

Wagemans stud
18. 06. 2007
0 views

Wagemans stud

sgtalk eg 2k4a1
16. 10. 2007
0 views

sgtalk eg 2k4a1

Asset Trade In
18. 06. 2007
0 views

Asset Trade In

arte moderno
18. 06. 2007
0 views

arte moderno

AP Presentation
18. 06. 2007
0 views

AP Presentation

Americas Tour
18. 06. 2007
0 views

Americas Tour

African Americans A Z
18. 06. 2007
0 views

African Americans A Z

Advantage Webinar
18. 06. 2007
0 views

Advantage Webinar

56 personnel Schlegel
18. 06. 2007
0 views

56 personnel Schlegel

VRP15
26. 02. 2008
0 views

VRP15

GIApowerpoint
06. 08. 2007
0 views

GIApowerpoint

heck
15. 10. 2007
0 views

heck

amore travagliato
18. 06. 2007
0 views

amore travagliato

George HseTrust HIV Lawn
06. 08. 2007
0 views

George HseTrust HIV Lawn

Missao ACentral
22. 10. 2007
0 views

Missao ACentral

fun at work presentatie
15. 06. 2007
0 views

fun at work presentatie

Ellesparlentdeshommes
15. 06. 2007
0 views

Ellesparlentdeshommes

donde esta mama1
15. 06. 2007
0 views

donde esta mama1

Cs101 Lec34
15. 06. 2007
0 views

Cs101 Lec34

Creationism
15. 06. 2007
0 views

Creationism

close your eyes
15. 06. 2007
0 views

close your eyes

Cat V2
15. 06. 2007
0 views

Cat V2

projectmamage
12. 10. 2007
0 views

projectmamage

Healthmanagement7
29. 02. 2008
0 views

Healthmanagement7

area riservata 2006
18. 06. 2007
0 views

area riservata 2006

dominguez hills
26. 08. 2007
0 views

dominguez hills

University Forum Feb 232005
03. 01. 2008
0 views

University Forum Feb 232005

4 cornerstone readership
18. 06. 2007
0 views

4 cornerstone readership

Where is the Donkey
01. 11. 2007
0 views

Where is the Donkey

agbus 435 lec9 f04
29. 10. 2007
0 views

agbus 435 lec9 f04

conchicoll
15. 10. 2007
0 views

conchicoll

nystax
27. 09. 2007
0 views

nystax

RussianAFMuseum
02. 10. 2007
0 views

RussianAFMuseum

weitz
24. 02. 2008
0 views

weitz

Jean McLellan
06. 08. 2007
0 views

Jean McLellan

Andrey Uroda
26. 10. 2007
0 views

Andrey Uroda

ED Lafco Present092805chew
26. 08. 2007
0 views

ED Lafco Present092805chew

buckinghamshirecc
26. 10. 2007
0 views

buckinghamshirecc

232nm14
30. 10. 2007
0 views

232nm14

Growingup Healthy with AFHK logo
06. 08. 2007
0 views

Growingup Healthy with AFHK logo